Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11485796 Inert format

Patent 11485796 was granted and assigned to Genmab A/S on November, 2022 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Applicant

0

Current Assignee

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Joyce I. Meesters0

Paul Parren0

Aran Frank Labrijn0

Edward Norbert Van Den Brink0

Janine Schuurman0

Joost J. Neijssen0

Date of Patent

November 1, 2022

0

Patent Application Number

167837200

Date Filed

February 6, 2020

0

Patent Citations

US Patent 10590206 Inert format

US Patent 10407501 Humanized or chimeric CD3 antibodies

0

US Patent 10465006 Humanized or chimeric CD3 antibodies

US Patent 10544220 Bispecific antibodies against CD3 and CD20

US Patent 11359015 Humanized or chimeric CD3 antibodies

Patent Citations Received

US Patent 11858995 Bispecific antibodies against CD3 and CD20 for treating chronic lymphocytic leukemia

0

Patent Primary Examiner

Meera Natarajan

0

Described herein are, proteins comprising amino acid substitutions in at least one of a first and a second polypeptide chain. Furthermore, is described the uses and methods related to said proteins.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11485796 Inert format

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool